Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
Fiche publication
Date publication
août 2017
Journal
JAMA
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Pr FORNECKER Luc-Matthieu
Tous les auteurs :
Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socié G,
Lien Pubmed
Résumé
Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.
Mots clés
Adult, Anti-Bacterial Agents, adverse effects, Azithromycin, adverse effects, Bronchiolitis Obliterans, etiology, Disease-Free Survival, Double-Blind Method, Female, Hematologic Neoplasms, mortality, Hematopoietic Stem Cell Transplantation, adverse effects, Humans, Intention to Treat Analysis, Male, Middle Aged, Recurrence, Respiratory Function Tests, Transplantation Conditioning, Transplantation, Homologous, Treatment Failure
Référence
JAMA. 2017 Aug;318(6):557-566